睿昂基因(688217) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥54,839,213.76, a decrease of 23.04% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was -¥3,494,450.21, representing a decline of 234.74% year-over-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥3,931,683.97, a decrease of 319.05% compared to the same period last year[2] - Total operating revenue for the first three quarters of 2024 was ¥189.63 million, a decrease of 4.0% compared to ¥198.82 million in the same period of 2023[21] - Net profit for the first three quarters of 2024 was ¥1.55 million, a significant decline from ¥11.07 million in the same period of 2023[23] - Basic and diluted earnings per share for the first three quarters of 2024 were both ¥0.10, down from ¥0.34 in the same period of 2023[24] Expenses and Costs - Research and development expenses totaled ¥12,653,201.13 in Q3 2024, down 33.56% year-over-year, accounting for 23.07% of operating revenue[3] - Research and development expenses for the first three quarters of 2024 were ¥46.85 million, a decrease of 7.5% from ¥50.37 million in the same period of 2023[21] - The net profit attributable to shareholders, excluding non-recurring gains and losses, for the third quarter was -3.19 million RMB, with management expenses increasing by 10.55% year-on-year due to higher depreciation and consulting fees[9] - Total operating costs increased to ¥192.93 million, up 2.4% from ¥188.55 million year-on-year[21] - Sales expenses increased to ¥59.34 million, up 10.0% from ¥53.72 million year-on-year[21] Cash Flow and Assets - The company reported a net cash flow from operating activities of ¥32,599,551.94 for the year-to-date, an increase of 10.87% compared to the same period last year[3] - The net cash inflow from operating activities in Q3 2024 was 20.31 million RMB, representing a year-on-year increase of 263.13%[9] - Cash flow from operating activities decreased to ¥204.44 million, compared to ¥275.59 million in the first three quarters of 2023, reflecting a decline of 26.0%[25] - The company's current assets totaled RMB 484.95 million as of September 30, 2024, a decrease from RMB 509.90 million as of December 31, 2023, representing a decline of approximately 4.1%[19] - The company's cash and cash equivalents decreased to RMB 133.58 million from RMB 161.68 million, reflecting a decline of approximately 17.4% year-over-year[18] Equity and Liabilities - The total equity attributable to shareholders at the end of Q3 2024 was ¥930,747,935.85, down 1.59% from the end of the previous year[3] - The company's total equity as of September 30, 2024, was RMB 948.10 million, down from RMB 967.68 million, reflecting a decrease of about 2.0%[20] - The total liabilities of the company decreased to RMB 66.93 million from RMB 76.48 million, a reduction of approximately 12.5%[20] Strategic Initiatives - The company increased its market promotion expenses by ¥4,600,300 to support the launch of new products, including the BCR-ABL fusion gene quantitative test[8] - The company organized two significant academic conferences in September and October 2024 to promote its new products and establish a rare gene alliance for leukemia[8] - The company has engaged a strategic consulting firm to plan and train for its three-year strategy, contributing to increased management expenses[9] - The company plans to use the repurchased shares for employee stock ownership plans or equity incentives in the future[17] Legal and Operational Challenges - The company has made arrangements for its operations to continue normally despite the ongoing investigation involving key personnel[16] - The company is currently facing legal consultation fees due to unexpected events in the third quarter, further impacting management costs[9] - The company’s major clients are medical institutions, which have been affected by the industry downturn, leading to increased credit impairment provisions[9] Share Repurchase - As of September 30, 2024, the company has repurchased a total of 669,621 shares, accounting for 1.20% of the total share capital of 55,855,896 shares, with a total expenditure of approximately RMB 17.02 million[17] - The company reported a maximum repurchase price of RMB 49.00 per share and a minimum of RMB 22.37 per share during the buyback period[17]